Hypertriglyceridemia Management

Definition

Hypertriglyceridemia is defined by elevated fasting triglyceride (TG) levels and is classified as: borderline high (150–199 mg/dL), high (200–499 mg/dL), very high (500–999 mg/dL), and severe (≥1000 mg/dL). It is associated with increased atherosclerotic cardiovascular disease (ASCVD) risk and, when severe, with acute pancreatitis. The condition is highly prevalent, frequently accompanied by diabetes, obesity, and metabolic syndrome.

Key Concepts

TG Classification and Clinical Consequences

• Moderate HTG (150–499 mg/dL): Associated with ASCVD risk through triglyceride-rich lipoprotein (TRL) remnant accumulation; atherogenicity per particle estimated equivalent to LDL cholesterol; associated with low HDL-C and elevated non-HDL-C; common in T2DM, CKM syndrome, and patients on standard lipid-lowering therapy
• Severe HTG (≥500–1000 mg/dL): Immediate risk of acute pancreatitis in addition to ASCVD risk; very severe (≥1000) markedly elevates pancreatitis risk
• FCS (Familial Chylomicronemia Syndrome): Monogenic LPL pathway defects; TG typically >1000 mg/dL; extremely high pancreatitis risk; distinct from polygenic hypertriglyceridemia

Existing Pharmacotherapy and Limitations

• Statins: 10–20% TG reduction (secondary effect)
• Prescription omega-3 fatty acids (EPA/DHA): 10–30% TG reduction; icosapent ethyl (REDUCE-IT): COR 2b for TG 150–499 on statin + ASCVD/diabetes (plagued by mineral oil placebo controversy — true benefit magnitude uncertain); no proven benefit in severe HTG
• Fibrates (fenofibrate preferred over gemfibrozil): 20–50% TG reduction; no ASCVD outcome benefit when added to statin; fenofibrate used for pancreatitis prevention in TG ≥500 mg/dL
• Niacin: 20–35% TG reduction; no CV outcome benefit on background statin (HPS2-THRIVE, AIM-HIGH); not recommended
• GLP-1 receptor agonists: ~10–20% TG reduction (secondary metabolic benefit)
• Gap: no previously available agent reduced TG by more than ~30–50% in the broad moderate HTG population

APOC3 Inhibition — Olezarsen (ESSENCE-TIMI 73b, Phase 3)

• Drug: Olezarsen — GalNAc-conjugated antisense oligonucleotide (ASO) targeting APOC3 mRNA; monthly subcutaneous injection; hepatocyte-selective delivery via asialoglycoprotein receptor
• Trial: ESSENCE-TIMI 73b; n=1,349; moderate HTG (TG 150–499 mg/dL + elevated CV risk); 160 sites in North America and Europe; 12-month treatment sources/olezarsen-essence-timi73b-nejm-2025 (high)
• Primary outcome (6-month TG, placebo-adjusted):
  • 50 mg: −58.4 pp (95% CI −65.1 to −51.7; P<0.001)
  • 80 mg: −60.6 pp (95% CI −67.1 to −54.0; P<0.001)
• TG normalization (<150 mg/dL): 85.0% (50 mg) and 88.7% (80 mg) vs 12.5% placebo at 6 months; 82.8% and 85.0% vs 20.6% at 12 months
• Beyond TG — atherogenic lipid burden:
  • APOC3 reduced 62–70% — mechanistic target confirmed
  • Remnant cholesterol reduced up to ~70% — largest anti-remnant reduction reported for any agent
  • VLDL-C reduced ~57%
  • Non-HDL-C reduced ~22%
  • ApoB reduced ~15% — total atherogenic particle reduction
  • LDL-C unchanged — consistent with APOC3's distinct mechanism (upstream of LDL production)
• No CV outcomes data: Trial not powered for MACE; a dedicated outcomes trial is required to confirm CV benefit
• Safety (see concepts/APOC3-Inhibition): Mild injection-site reactions; mild transaminase elevations (no clinically significant hepatotoxicity); modest thrombocytopenia (not significant vs placebo); small HbA1c increase in diabetics
• FDA-approved for FCS: Olezarsen already approved for familial chylomicronemia syndrome (reduced pancreatitis in BALANCE trial); ESSENCE-TIMI 73b data supports potential label expansion to moderate HTG

Emerging APOC3 Competitor

• Plozasiran (siRNA, ARO-APOC3): ~57–79% APOC3 reduction and ~44–62% TG reduction in mixed hyperlipidemia; phase 3 data in severe HTG/FCS; class effect comparable to olezarsen with similar safety signals (mild transaminase elevation, small HbA1c rise)

Other Novel Triglyceride-Lowering Approaches in Development

Clinical Management Framework

• TG 150–499 mg/dL + elevated CV risk:
  • Lifestyle modification first (low added sugar, reduced refined carbs, saturated fat, alcohol; aerobic exercise ≥150 min/wk)
  • Optimise statin ± ezetimibe (primary ASCVD risk goal)
  • Icosapent ethyl 4 g/day if LDL-C <100 on statin (COR 2b — ACC/AHA 2026; COR IIa B — ESC 2025)
  • Olezarsen 80 mg SC monthly — FDA-approved for FCS; ESSENCE-TIMI 73b supports use in moderate HTG (pending label expansion); 60 pp TG reduction vs 12.5% TG normalization rate without treatment
• TG 500–999 mg/dL:
  • Fibrate (fenofibrate preferred — fewer DDI vs gemfibrozil) to reduce pancreatitis risk
  • Prescription omega-3 fatty acids as add-on
  • APOC3 inhibition (olezarsen/plozasiran) emerging as dominant strategy — ongoing CORE-TIMI 72a/72b trials
• TG ≥1000 mg/dL / FCS:
  • Very-low-fat diet (<10–15% of calories from fat); eliminate alcohol/refined sugars
  • Fibrate or prescription omega-3 FA
  • Olezarsen: COR 1 (ACC/AHA 2026); Volanesorsen: COR IIa B (ESC 2025; EMA-approved only — not FDA)

Contradictions / Open Questions

• No CV outcomes proof for APOC3 inhibition in moderate HTG: Genetic LOF APOC3 data support ASCVD benefit, but ESSENCE-TIMI 73b was not powered for MACE. TRL remnants are atherogenic per particle, and APOC3 inhibition reduces both remnant cholesterol and ApoB — yet whether this translates to clinical event reduction requires a dedicated outcomes trial sources/olezarsen-essence-timi73b-nejm-2025 (high)
• REDUCE-IT placebo controversy limits IPE utility: The 25% MACE reduction in REDUCE-IT (EPA only, mineral oil placebo) is disputed; STRENGTH (EPA+DHA, corn oil placebo) was neutral. ACC/AHA 2026 gives icosapent ethyl only COR 2b; ESC 2025 gives COR IIa B — different societies weight the evidence differently
• No head-to-head APOC3 ASO vs siRNA comparison: Olezarsen (ASO) and plozasiran (siRNA) both target APOC3 with similar clinical efficacy (~58–79% TG reduction); no direct comparison trial; selection may depend on formulary access and administration preferences
• Whether TG-lowering is causally or only correlatively linked to ASCVD outcomes: Fibrates reduce TG significantly but failed to reduce MACE on background statin. The TRL remnant—not TG per se—may be the atherogenic moiety; APOC3 inhibition lowers remnant cholesterol more potently than fibrates, which may explain why outcomes data are eagerly awaited
• FCS treatment: regional divergence (olezarsen/FDA vs volanesorsen/EMA): Both target APOC3 but are different molecules with different regulatory approvals; international patients face access disparities

Connections

• Related to concepts/APOC3-Inhibition — mechanism and clinical data for APOC3-targeting therapies
• Related to concepts/Dyslipidemia-Management — full lipid management framework including TG section
• Related to entities/Olezarsen — the lead clinical APOC3 ASO
• Related to concepts/ASCVD-Risk-Assessment — TG and remnant cholesterol as emerging ASCVD risk factors

Sources

• sources/olezarsen-essence-timi73b-nejm-2025 — ESSENCE-TIMI 73b Phase 3 RCT; olezarsen −58–61 pp TG; 85–89% TG normalization; remnant cholesterol up to −70%